Codiak BioSciencesÂ Inc (CDAK) Peer Comparison

$0.01

$0.00 (-25.62%)

As on 07-Jun-2023 09:30EDT

Market cap

$3 Mln

Revenue (TTM)

$34 Mln

P/E Ratio

--

P/B Ratio

0.5

Div. Yield

0 %

Edit

	Codiak BioSciencesÂ Inc (CDAK)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Market cap ($ Mln)	3	17,326	13,400	12,305	12,277
Revenue ($ Mln)	34	2,782	2,436	670	1,664
Net Profit ($ Mln)	-29.24	491.50	860.62	-319.95	413.60
Net Margin (%)	-43.32	17.67	35.33	-47.79	24.86
RoE (%)	-66.97	110.09	42.98	-71.14	430.03
Price to Earnings	--	36.49	17.01	--	31.17
Price-To-Book	0.55	39.43	7.27	26.44	83.92

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Codiak BioSciencesÂ Inc (CDAK)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Operating Revenue	33.57	1,142.38	1,434.97	138.29	443.31
Cost of Revenue	4.51	814.22	52.87	--	81.41
Gross Profit	22.94	328.16	1,382.10	138.29	361.90
Operating Expenses	104.73	129.54	1,095.43	287.32	86.00
Operating Profit (EBIT)	-53.30	198.62	286.67	-149.04	275.90
Other Income	33.91	3.34	-0.18	2.07	-19.86
Profit before Tax	-39.23	201.85	294.15	-140.85	248.52
Provision for Tax	-9.99	20.00	63.09	0.00	-154.19
Profit after Tax (Net Income)	-29.24	181.85	231.06	-140.85	402.71
Minority Interest	0.00	--	--	--	--
Consolidated Profit	-17.42	181.85	231.06	-140.85	402.71

Liabilities ($ Mln)

	Codiak BioSciencesÂ Inc (CDAK)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Shareholder's Funds	38.93	952.93	2,210.62	408.82	196.95
Minority Interest	0.00	--	--	--	--
Non-Current Liabilities	81.01	149.79	68.03	154.79	790.33
Current Liabilities	14.46	557.22	337.59	146.54	117.15
Total Liabilities	171.67	1,659.94	2,616.24	710.15	1,104.43

Assets ($ Mln)

	Codiak BioSciencesÂ Inc (CDAK)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Non-Current Assets	73.16	969.02	781.49	325.55	178.14
Current Assets	61.23	690.91	1,834.75	384.60	926.29
Total Assets	171.67	1,659.94	2,616.24	710.15	1,104.43
Total Debt*	61.28	130.97	51.27	25.55	876.67
Net Current Assets	46.78	133.70	1,497.16	238.06	809.14

Cashflow ($ Mln)

	Codiak BioSciencesÂ Inc (CDAK)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Cash From Operating Activities	-74.14	263.33	400.80	171.31	299.44
Cash Flow from Investing Activities	-3.25	-31.36	-42.88	-141.68	-406.29
Cash from Financing Activities	65.41	-44.45	-14.80	11.31	77.87
Net Cash Inflow / Outflow	-11.98	187.51	52.64	40.85	-28.98

Ratios

Profitability Ratios

	Codiak BioSciencesÂ Inc (CDAK)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
ROCE (%)	-3.99	18.14	11.03	-30.71	49.66
ROE (%)	-66.97	20.68	11.30	-32.36	231.44
ROA (%)	-17.68	11.92	9.72	-22.85	47.82
EBIT Margin (%)	-158.77	--	--	--	--
Net Margin (%)	-43.32	15.87	16.10	-100.35	95.10
Cash Profit Margin (%)	0.00	--	--	--	--

Growth Ratios

	Codiak BioSciencesÂ Inc (CDAK)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Revenue Growth (%)	98.92	0.23	0.45	0.57	0.66
EBIT Growth (%)	22.72	--	--	--	--
Net Profit Growth (%)	59.27	25.08	106.71	-66.58	211.97
EPS Growth (%)	--	0.25	1.04	-0.64	2.14
Book Value Growth (%)	--	--	--	--	--

Valuation Ratios

	Codiak BioSciencesÂ Inc (CDAK)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Price / Earnings	--	45.17	25.57	-46.33	14.40
Price / Book Value	--	8.62	2.67	15.96	29.45
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	0.23	35.34	14.96	-46.64	21.28
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Codiak BioSciencesÂ Inc (CDAK)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Debt to Equity	0.66	0.14	0.02	0.06	4.45
Short term debt to equity ratio	0.08	0.17	0.00	0.01	0.45
Current Ratio	4.24	1.24	5.43	2.62	7.91
Quick Ratio	4.24	--	5.35	2.59	7.45
Interest Coverage	-5.44	1,923.40	--	-23.01	36.66

Operating Efficiency Ratios

	Codiak BioSciencesÂ Inc (CDAK)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Debtors to sales (%)	0.00	16.32	19.70	7.42	20.52
Asset Turnover	0.20	0.75	0.60	0.22	0.53
Receivable days	10.51	55.54	56.45	14.66	77.74
Inventory Days	--	0.00	167.40	--	257.19
Payable days	--	11.71	165.41	--	7.78
Cash Conversion Cycle	--	48.64	58.44	--	327.15

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly